Overview of the drug development pipeline for endometriosis
It has been observed that endometriosis is a condition in which cells similar to the cells in the endometrium (tissue layer that normally covers the inner part of the uterus) grow outside the uterus. There are no definite symptoms of endometriosis, but sometimes it can lead to painful menstruation, lower abdominal pain, or pain during sexual intercourse. At times, endometriosis can also lead to infertility. The primary regions where endometriosis occurs are within the fallopian tubes, outside the fallopian tubes and ovaries, the outer surfaces of the uterus and intestines, and on the surface of the pelvic cavity. Endometriosis is very rarely found on the surface of the liver, old scars, lungs, or the brain. Several public and private companies are focused on the development of drug molecules for the treatment of endometriosis. Monotherapy is emerging as the most efficient approach for the treatment of endometriosis.
According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for the treatment of endometriosis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of endometriosis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
- Eli Lily
- Endoceutics
- Enteris BioPharma
Therapeutic assessment of the drug development pipeline for endometriosis by route of administration
- Oral
- Intramuscular
- Intravaginal
- Subcutaneous
- Unspecified
The oral route of administration (ROA) involves the administration of the drug directly into the mouth cavity, which will have a more direct effect on the target cells. The intramuscular ROA is done by directly delivering the drug molecules into the muscles while intravaginal involves administration of the drug inside the vagina.
Therapeutic assessment of the drug development pipeline for endometriosis by therapy
- Monotherapy
According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for endometriosis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug therapy molecules in the various development stages for endometriosis?
- What are the companies that are currently involved in the development of drug molecules for endometriosis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.